Clinical Trial Update: Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of ligelizumab in adolescents and adults with chronic inducible urticaria was terminated; results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inducible Urticaria

Drugs mentioned

• Ligelizumab (ligelizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Inducible Urticaria | Phase 3 | Status: TERMINATED | Results posted: 2023-09-15